Spero Therapeutics Inc. (2HA)
XDUS 
Summary
2HA Chart
Spero Therapeutics, Inc. (SPRO) Q2 2026 Earnings Call Transcript
Spero Therapeutics, Inc. (SPRO) Q2 2026 Earnings Call Transcript
Spero Therapeutics Q2 Earnings Call Highlights
Spero Therapeutics NASDAQ: SPRO used its second-quarter update to outline a strategic shift toward immune-mediated diseases, supported by the FDA approval of Utebzi and a new licensing agreement for SP001, an antibody candidate the company plans to develop initially for IgG4-related disease.
Spero Therapeutics: 'Buy' On Utebzi Royalty Deal For Funding And SP001 In-Licensing
Spero Therapeutics is initiated with a "Buy" rating, driven by its strategic pivot to immunology and strong non-dilutive financing. SPRO secured FDA approval for Utebzi and a $105M royalty deal, enabling funding for SP001 development without shareholder dilution. SP001, a third-generation anti-CD40L antibody, targets IgG4-RD and Sjögren's disease, with phase 2 trials planned for 2027 and a differentiated, B-cell-sparing MOA.
Spero Therapeutics Inc. (2HA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Spero Therapeutics Inc. ever had a stock split?
Spero Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Esther Rajavelu CEO | XDUS Exchange | US84833T1034 ISIN |
| US Country | 25 Employees | - Last Dividend | - Last Split | 2 Nov 2017 IPO Date |
Overview
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company that specializes in the development and commercialization of innovative treatments targeting multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. Founded in 2013, the company is committed to addressing the growing challenge of antibiotic resistance through its focused research and development efforts. With its headquarters in Cambridge, Massachusetts, Spero Therapeutics stands at the forefront of combating infections that are increasingly resistant to existing antibiotic treatments, aligning its mission with a critical global health need.
Products and Services
The company's pipeline consists of promising candidates that include:
- Tebipenem Pivoxil Hydrobromide (HBr): This oral carbapenem-class antibiotic is being developed for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, in adults. As the first oral drug in its class, tebipenem HBr represents a significant advancement in the treatment of these infections, potentially providing an effective alternative to intravenous (IV) antibiotics.
- SPR206: This IV-administered antibiotic is designed to combat MDR Gram-negative pathogens, such as carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa. Its development focuses on addressing severe bacterial infections within hospital settings, where resistance to existing antibiotics is most prevalent.
- SPR720: An innovative oral antibiotic agent aimed at treating non-tuberculous mycobacterial (NTM) pulmonary disease. This stands as a novel approach to tackling a growing health concern, offering hope to patients suffering from these chronic, debilitating infections that are difficult to treat with current medications.
In support of developing these significant product candidates, Spero Therapeutics has entered into strategic licensing agreements with several industry players. These partnerships include an agreement with Meiji Seika Pharma Co., Ltd. for the development of tebipenem HBr; Everest Medicines to oversee the development, manufacturing, and commercialization of SPR206 across Greater China, South Korea, and Southeast Asia; and an agreement with Vertex Pharmaceuticals Incorporated covering patents related to SPR720 and its active metabolite, SPR719.
